Apr 24, 2024

Featuring perspectives from Dr Naveen Pemmaraju, including the following topics:

• Recent developments in management approaches for myelofibrosis prior to ASH 2023 (0:00)
• Updated data with navitoclax in combination with ruxolitinib for patients with myelofibrosis (12:35)
• Key findings with pelabresib in combination with...

Apr 19, 2024

Featuring perspectives from Dr Andrew H Ko and Dr Eileen M O’Reilly, including the following topics.

• Selection and Sequencing of Therapy for Patients with Metastatic Pancreatic Adenocarcinoma (PAD) — Dr Ko (0:00)
• Biomarker-Based Strategies for Metastatic PAD; Novel Investigational Approaches — Dr O’Reilly...

Apr 19, 2024

Featuring perspectives from Dr Kristen K Ciombor and Dr John Strickler, including the following topics.

• Select Biomarker-Directed Approaches for Colorectal Cancer (CRC) — Dr Ciombor (0:00)
• HER2-Targeted Approaches for Metastatic CRC (mCRC); Other Available and Emerging Therapeutic Strategies — Dr Strickler...

Apr 19, 2024

Featuring perspectives from Dr Ghassan Abou-Alfa and Dr Richard S Finn, including the following topics.

• Introduction (0:00)
• Hepatocellular Carcinoma (HCC) — Dr Abou-Alfa (8:30)
• Biliary Tract Cancers (BTCs) — Dr Finn (33:16)

CME information and select...

Apr 19, 2024

Featuring perspectives from Dr Yelena Y Janjigian and Dr Samuel J Klempner, including the following topics.

• Current and Potential Role of Immune Checkpoint Inhibitors in the Treatment of Gastroesophageal Cancers — Dr Klempner (0:00)
• Other Available and Emerging Therapeutic Approaches — Dr Janjigian (31:42)

CME...